T-Cell study funded

The National Institutes of Health (NIH) National Cancer Institute has granted $124,000 to Aastrom Biosciences, Inc. to develop an immunotherapeutic treatment of malignant melanoma using AastromReplicell System cell production technology.

Related Videos
Related Content

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.